Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

KemPharm Inc (KMPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

KemPharm Inc (KMPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

KemPharm Inc (KMPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

KemPharm Inc (KMPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

KemPharm Inc (KemPharm) is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company's product pipeline includes KP415, methylphenidate drug for ADHD; KP201/IR, KP511/ER, KP606/IR and KP746 drugs for the treatment of pain. It also develops KP303 a quetiapine antipsychotic drug that treats multiple central nervous system disorders. KemPharm uses ligand activated therapy (LAT) a platform technology to produce new molecular entity prodrugs. The company offers its products in the therapeutic areas such as Attention deficit hyperactivity disorder (ADHD), pain, and other central nervous system indications. KemPharm is headquartered in Coralville, Iowa, the US.

KemPharm Inc (KMPH)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

KemPharm Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

KemPharm Enters into Licensing Agreement with Genco Sciences 11

KemPharm Enters into Licensing Agreement with Acura Pharma 12

Equity Offering 13

KemPharm Prices Public Offering of Shares for USD25 Million 13

KemPharm to Raise USD50 Million in Public Offering of Shares 15

KemPharm to Raise USD20 Million in Public Offering of Shares 16

KemPharm to Raise USD62.7 Million in Public Offering of Shares 17

KemPharm Raises USD56 Million in IPO 18

Debt Offering 20

KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20

KemPharm Raises USD10 Million in Private Placement of Notes 22

Asset Transactions 23

Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23

KemPharm Inc-Key Competitors 24

KemPharm Inc-Key Employees 25

KemPharm Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Aug 09, 2018: KemPharm reports second quarter 2018 results 27

May 10, 2018: KemPharm Reports Q1 2018 Results 29

May 10, 2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results 31

Mar 29, 2018: KemPharm Reports Fourth Quarter and Year End 2017 Results 34

Nov 09, 2017: KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update 36

Aug 10, 2017: KemPharm Reports Second Quarter 2017 Results 37

May 10, 2017: KemPharm Reports First Quarter 2017 Results 38

Mar 09, 2017: KemPharm Reports Fourth Quarter and Year End 2016 Results 39

Product News 40

11/16/2017: KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA 40

11/06/2017: KemPharm Receives USAN Approval for Asalhydromorphone as Nonproprietary Name for Novel Prodrug Candidate, KP511 41

07/09/2018: KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD 42

06/09/2017: KemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids 44

05/10/2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug 45

03/20/2018: KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD 46

Product Approvals 47

Sep 20, 2017: KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate 47

Clinical Trials 48

Sep 11, 2018: KemPharm announces positive topline results from oral human abuse potential trial of KP415 prodrug 48

Jan 08, 2018: KemPharm Initiates Pivotal Efficacy Trial of KP415 49

Aug 10, 2017: KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial 50

Mar 16, 2017: KemPharm Presents Clinical Data for KP511 at American Academy of Pain Medicine's Annual Meeting 51

Jan 09, 2017: KemPharm Reports Positive Data from Phase 1 Intranasal Pharmacokinetic Study of KP511, An Investigational Prodrug of Hydromorphone for the Treatment of Pain 52

Other Significant Developments 54

Oct 11, 2018: Kempharm provides highlights from KOL investor event focused on the ADHD treatment landscape 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

KemPharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

KemPharm Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

KemPharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

KemPharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

KemPharm Inc, Deals By Therapy Area, 2012 to YTD 2018 9

KemPharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

KemPharm Enters into Licensing Agreement with Genco Sciences 11

KemPharm Enters into Licensing Agreement with Acura Pharma 12

KemPharm Prices Public Offering of Shares for USD25 Million 13

KemPharm to Raise USD50 Million in Public Offering of Shares 15

KemPharm to Raise USD20 Million in Public Offering of Shares 16

KemPharm to Raise USD62.7 Million in Public Offering of Shares 17

KemPharm Raises USD56 Million in IPO 18

KemPharm Raises USD86.3 Million in Private Placement of 5.5% Senior Notes Due 2021 20

KemPharm Raises USD10 Million in Private Placement of Notes 22

Shire Acquires Amphetamine Amino Acid Conjugate Products from KemPharm 23

KemPharm Inc, Key Competitors 24

KemPharm Inc, Key Employees 25

KemPharm Inc, Other Locations 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

KemPharm Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person